The two faces of the 'good' cholesterol

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 10, 2007, Pages 697-705

  Ansell, Benjamin J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; INFLAMMATION; NUTRITIONAL STATUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK ASSESSMENT;

CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NUTRITIONAL STATUS; OXIDATIVE STRESS; RISK ASSESSMENT;

EID: 36048929740     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.10.697     Document Type: Review

References (28)

1. Gordon DJ, Probstfield JL. Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
2. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med 1987; 317:1237-1245.
3. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
4. Brown BG, Zhao, XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
5. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT a randomized controlled trial. JAMA 2001; 285:1585-1591.
6. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20:1253-1268.
7. Mosca L, Appel U. Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol 2004; 24:29e-50e.
8. Brousseau ME, Schaefer EJ, Wolfe MI, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.
9. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27:257-260.
10. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495-1508.
11. Navab M, Imes SS, Hama SY, et al. Monocytetransmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039-2046.
12. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-2756.
13. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006; 48:715-720.
14. Navab M. Hama SY, Hough GP, Subbanagounder G. Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42:1308-1317.
15. Hasselwander O, McEneny J, McMaster D, et al. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis 1999; 143:125-133.
16. Van Lenten BJ, Hama SY, cle Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-2767.
17. Van Lenten BJ, Wagner AC, Nayak DR Hama S, Navab M. Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103:2283-2288.
18. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein m etabolism in patients with severe sepsis. Crit Care Med 2003; 31:1359-1366.
19. McMahon M, Grossman J, Fitzgerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541-2529.
20. Manzi S, Meilahn EN. Rairie JE. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-415.
21. Solomon DH, Karkoon EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-1307.
22. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114:529-541.
23. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993-1007.
24. Roberts CK, Ng C, Hama S, Ellseo AJ, Barnard RJ. Effect of a short-term diet and exercise intervention on inflammatory/ anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006; 101:1727-1732.
25. Charles-Schoeman C, Khanna D, Furst DE, et al. Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007; 34:1459-1464.
26. Navab M, Anantharamaiah GM, Reddy S, et al. Apolipoprotein A-I mimetic pepticles. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331.
27. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins; synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1426-1432.
28. Dunbar RL, Bloedon LT, Duffy D, et al. Daily oral administration of the apolipoprotein Al mimetic pepticle D-4F in patients with coronary heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function. Paper presented at American College of Cardiology 56th Annual Scientific Session, 2007; New Orleans, LA.